**Supplementary table 2. Additional profiles of colorectal cancer..**

|  | Propofol group | Sevoflurane group | *P* |
| --- | --- | --- | --- |
| (n = 76) | (n = 77) |  |
| Maximum size of mass (cm) | | |  |
| Width | 4.5 (2.8 - 6.0) | 3.9 (2.6 - 6.0) | 0.829 |
| Length | 3.2 (2.1 - 4.0) | 3.0 (2.0 - 4.5) | 0.884 |
| Height | 1.2 (0.8 - 1.9) | 1.2 (0.8 - 2.0) | 0.718 |
| Expression of protein in pathologic specimens | | |  |
| Epidermal growth factor receptor | 54 (71.1%) | 52 (67.5%) | 0.637 |
| *p53* | 57 (75.0%) | 52 (67.5%) | 0.308 |
| Incidence of gene mutations in pathologic specimens | | |  |
| *KRAS* gene | 22 (28.9%) | 29 (37.7%) | 0.253 |
| *NRAS* gene | 7 (9.2%) | 9 (11.7%) | 0.617 |
| *BRAF* gene | 6 (7.9%) | 8 (10.4%) | 0.593 |
| Analysis for pathologic specimens | | |  |
| Microsatellite instability | 7 (9.2%) | 8 (10.4%) | 0.806 |
| Loss of heterozygosity | 24 (31.6%) | 33 (42.9%) | 0.149 |

Data are expressed as medians (25% -75%) or numbers (%).